Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

563 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
Navari RM, Einhorn LH, Loehrer PJ Sr, Passik SD, Vinson J, McClean J, Chowhan N, Hanna NH, Johnson CS. Navari RM, et al. Among authors: johnson cs. Support Care Cancer. 2007 Nov;15(11):1285. doi: 10.1007/s00520-007-0248-5. Epub 2007 Mar 21. Support Care Cancer. 2007. PMID: 17375339 Clinical Trial.
Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.
Adra N, Albany C, Brames MJ, Case-Eads S, Johnson CS, Liu Z, Fausel CA, Breen T, Hanna NH, Hauke RJ, Picus J, Einhorn LH. Adra N, et al. Among authors: johnson cs. Support Care Cancer. 2016 Jul;24(7):2837-42. doi: 10.1007/s00520-016-3100-y. Epub 2016 Feb 2. Support Care Cancer. 2016. PMID: 26838019 Free article. Clinical Trial.
Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH. Albany C, et al. Among authors: johnson cs. J Clin Oncol. 2012 Nov 10;30(32):3998-4003. doi: 10.1200/JCO.2011.39.5558. Epub 2012 Aug 20. J Clin Oncol. 2012. PMID: 22915652 Clinical Trial.
Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.
Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, Breen T, McClean J, Stephens D, Whalen C, Sutton G. Matei D, et al. Among authors: johnson cs. Cancer. 2008 Aug 15;113(4):723-32. doi: 10.1002/cncr.23605. Cancer. 2008. PMID: 18618737 Free article. Clinical Trial.
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W, Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L; Hoosier Oncology Group; US Oncology. Hanna N, et al. J Clin Oncol. 2008 Dec 10;26(35):5755-60. doi: 10.1200/JCO.2008.17.7840. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001323 Clinical Trial.
A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study.
Cardenes HR, Moore AM, Johnson CS, Yu M, Helft P, Chiorean EG, Vinson J, Howard TJ, Stephens AW, Tai DF, Loehrer PJ Sr. Cardenes HR, et al. Among authors: johnson cs. Am J Clin Oncol. 2011 Oct;34(5):460-5. doi: 10.1097/COC.0b013e3181e9c103. Am J Clin Oncol. 2011. PMID: 20881474 Clinical Trial.
Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology.
Jalal SI, Riggs HD, Melnyk A, Richards D, Agarwala A, Neubauer M, Ansari R, Govindan R, Bruetman D, Fisher W, Breen T, Johnson CS, Yu M, Einhorn L, Hanna N. Jalal SI, et al. Among authors: johnson cs. Ann Oncol. 2012 Jul;23(7):1730-8. doi: 10.1093/annonc/mdr565. Epub 2011 Dec 9. Ann Oncol. 2012. PMID: 22156624 Free article. Clinical Trial.
Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Chiorean EG, Schneider BP, Akisik FM, Perkins SM, Anderson S, Johnson CS, DeWitt J, Helft P, Clark R, Johnston EL, Spittler AJ, Deluca J, Bu G, Shahda S, Loehrer PJ, Sandrasegaran K, Cardenes HR. Chiorean EG, et al. Among authors: johnson cs. Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):284-91. doi: 10.1016/j.ijrobp.2014.02.024. Epub 2014 Apr 11. Int J Radiat Oncol Biol Phys. 2014. PMID: 24726286 Clinical Trial.
563 results